Adverum BiotechnologiesADVM
13F holders, Q2 2024 (June 30)2holders −1
0new positions
1sold out
$6.86avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Adverum Biotechnologies Inc. (ADVM) in their 13F filings, down 1 from Q1 2024. 0 opened new positions and 1 sold out. The largest holders were TCG Crossover Management, LLC ($13.8M) and Versant Venture Management, LLC ($3.5M).
- Company
- Adverum Biotechnologies Inc.
- CUSIP
- 00773U108
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $15.1M |
All 13F filers, Q1 2024 → Q2 2024: 1,069,245 shares sold, net −1,069,245 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| TCG Crossover Management, LLC | 1.44% | No change | 2,008,340 | $13.8M |
| Versant Venture Management, LLC | 4.50% | Reduce 0.0% | 506,821 | $3.5M |
"% of holder's portfolio" is ADVM's weight in each manager's 13F, not the share of Adverum Biotechnologies Inc. the manager owns.